DocWire News Editors

DocwireNews

An international phase III study compared treatment outcomes between once-weekly selinexor plus bortezomib-dexamethasone (XVd), and twice-weekly bortezomib-dexamethasone alone (Vd) in patients with multiple myeloma (MM) after prior treatments. Their research found significantly improved outcomes in the XVd group.&nbsp;According to Shambavi Richard, MD, and colleagues, &ldquo;XVd provided a non-[immunomodulatory drug]-based regimen with superior benefits over Vd&rdquo; in a number of outcomes across both test groups. Their study was published in the American Journal of Hematology.&nbsp;A total of 402 patients with MM who had undergone one to three prior treatment regimens were randomized to either once-weekly XVd (n = 195), or twice-weekly Vd (n = 207) groups. The primary endpoint was progress-free survival (PFS), assessed by an independent review committee. Secondary endpoints included overall survival, overall response rate, duration of response (DOR), time to next therapy (TTNT), rates of grade II or higher peripheral neuropathy, and safety.&nbsp;Of the participants, 141 patients with MM displayed high-risk cytogenetics (XVd, n = 70; Vd, n = 71), and 261 displayed standard-risk cytogenetics (XVd, n = 125; Vd, n = 136). Among patients with high-risk MM, median PFS was 12.91&thinsp;months for XVd and 8.61&thinsp;months for Vd (HR=0.73; 95% CI, 0.4673-1.1406, p = 0.082), and ORRs were 78.6% and 57.7%, respectively (OR=2.68; p =&thinsp;0.004). In the standard-risk subgroup, median PFS was 16.62&thinsp;months for XVd and 9.46&thinsp;months for Vd (HR=0.61; p = 0.004), and ORRs were 75.2% and 64.7%, respectively (OR=1.65; p = 0.033). The safety profiles of XVd and Vd in both subgroups were consistent with the overall population.&nbsp;The authors addressed several limitations of their study, including the fact that the trial was not designed to statistically compare outcomes between high-risk and standard-risk patients.&nbsp;Ultimately, the researchers suggested that selinexor can confer benefits to patients with MM regardless of cytogenetic risk and associated the XVd regimen with superior median outcomes relative to the Vd regimen.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

BOSTON Trial: Bortezomib and Dexamethasone With and Without Selinexor in Multiple Myeloma

Oncology

An international phase III study compared treatment outcomes between once-weekly selinexor plus bortezomib-dexamethasone (XVd), and twice-weekly bortezomib-dexamethasone alone ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe